- AU$8.30m
- AU$24.26m
- AU$9.31m
Cann Group half year results
Half Yearly Report and Accounts
PRE_NR Ends: 09:30:12
Cann to present half year results webinar
Cann to begin recruitment for CBD phase 3 clinical trial
PRE_NR Ends: 12:41:14
Brief: Cann Group Ltd Says Qtrly Unaudited Sales Revenue A$2.06 Million, Up 65% Q-O-Q
Quarterly Activities/Appendix 4C Cash Flow Report
PRE_NR Ends: 08:38:03
Brief: Cann Group Says Granted GMP Licence & Other Regulatory Updates
Australia's Cann Group jumps most in over two months after regulatory approval
Cann granted GMP licence & other regulatory updates
PRE_NR Ends: 09:33:15
Brief: Cann Group Says Acquisition Of Zalm Therapeutics By Rua Bioscience Approved By Rua Shareholders
Rua shareholders approve acquisition of Zalm Therapeutics
Application for quotation of securities - CAN
Issue of performance rights to senior executives
Notification regarding unquoted securities - CAN
Cann receives $2.186m R&D tax rebate